Deprecated: Creation of dynamic property cls_session::$session_data_table is deprecated in /www/sites/www.188bio.com/index/systems/cls_session.php on line 49
CST/Bortezomib #2204/2204S188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

CST/Bortezomib #2204/2204S

Product Usage Information

Bortezomib is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 2.5 mg in 6.51 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-1000 nM for 2-48 hours. Soluble in DMSO and ethanol at 200 mg/ml, very poorly soluble in plain water.

Storage:

Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

384.24 g/mol

Purity:

99%

Molecular Formula:

C19H25BN4O4

Background

Bortezomib (C19H25BN4O4), a boronic acid dipeptide, is a specific, potent, and reversable proteasome inhibitor that has also been shown to have a stabilizing effect on proteins that inhibit cell survival and cell cycle progression, such as p53 (1,2). Researchers have demostrated that bortezomib inhibits activation and nuclear translocation of NF-κB, subsequently decreasing early tumor survival (3). The increase in bortezomib-stablilized, misfolded, and ubiquitinated proteins that interfere with cell survival and other important pathways further support its anti-tumor effects (3).

  1. Williams, S.A. and McConkey, D.J. (2003) Cancer Res 63, 7338-44.
  2. Poulaki, V. et al. (2007) Invest Ophthalmol Vis Sci 48, 4706-19.
  3. Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66.
新闻动态
行业前沿
技术文章
最新产品